查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1994510

2026年全球心血管基因檢測市場報告

Cardiovascular Genetic Testing Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，心血管基因檢測市場規模迅速擴張。預計該市場將從2025年的39.3億美元成長到2026年的43.5億美元，複合年成長率（CAGR）為10.8%。過去幾年成長要素包括：人們對遺傳性心血管疾病的認知不斷提高、分子診斷技術的進步、基因定序成本的下降、遺傳諮詢服務的普及以及心血管基因組學研究的活性化。

預計未來幾年心血管基因檢測市場將快速成長，到2030年將達到66.2億美元，複合年成長率（CAGR）為11.0%。預測期內的成長預計將受到以下因素的推動：對精準醫療方法的需求不斷成長、基於人群的基因篩檢日益普及、人工智慧驅動的突變分析不斷擴展、基因組學在臨床決策中的應用不斷深入，以及人們對心血管疾病預防保健的日益重視。預測期內的關鍵趨勢包括：預測性基因風險評估的普及、多基因panel檢測的廣泛應用、生物資訊學和人工智慧分析的融合發展、藥物藥物基因體學學檢測應用的擴展，以及人們對個人化心血管保健的日益關注。

預計未來幾年，心血管疾病盛行率的上升將推動心血管基因檢測市場的成長。心血管疾病（CVD）涵蓋多種影響心臟和血管的疾病，例如心肌梗塞、中風和高血壓。導致心血管疾病盛行率上升的一個主要因素是與都市化相關的久坐生活方式，這種生活方式會導致肥胖、高血壓和代謝性疾病。心血管疾病發生率的上升正在推動心血管基因檢測的需求。早期識別遺傳風險有助於制定個人化的預防策略和標靶治療，從而降低嚴重心臟併發症的風險。例如，根據總部位於美國的非營利組織美國心臟協會的數據，截至2024年1月，心血管疾病的年齡調整死亡率預計將上升至2024年的每10萬人233.3人，比2023年的每10萬人224.4人增加4.0%。因此，心血管疾病盛行率的上升正在推動心血管基因檢測市場的成長。

心血管基因檢測市場的主要企業正致力於開發創新解決方案，例如醫生主導的檢測，以確保醫療必要性，並根據患者的個別情況進行個人化檢測，從而減少不必要的檢測及其相關成本。醫師主導的檢測是指醫療專業人員為指南病患健康評估、監測或管理而要求進行的診斷程序。例如，2025年9月，總部位於美國的非營利綜合學術醫療保健系統麻省總醫院布萊根醫療中心與博德臨床實驗室和麻省總醫院布萊根分子醫學實驗室合作，推出了一項基因檢測，用於評估八種心血管疾病的遺傳風險。這項由臨床醫生主導的檢測以自費形式提供，可評估患者對心房顫動、冠狀動脈疾病、第2型糖尿病、高膽固醇症膽固醇血症、高血壓、胸主動脈瘤和靜脈血栓栓塞症等疾病的遺傳易感性。此檢測方法的開發利用了美國國立衛生研究院 (NIH) 「我們所有人」(All of Us) 研究計畫中 236,393 名參與者的基因型和臨床數據。研究人員使用 PRSmix（一種彈性網路建模技術，可將多個成分評分合併為針對每種疾病的單一綜合風險評分）整合了公開的多基因風險評分。高解析度遺傳數據由博德臨床實驗室 (Broad Clinical Labs) 透過混合基因組-EXOME檢測獲得，結果由獲得 CLIA 認證的麻省總醫院布萊根分子醫學實驗室 (Mass General Brigham Laboratory for Molecular Medicine) 進行分析，並以易於理解的報告形式呈現給患者。

目錄

第1章：執行摘要

第2章 市場特徵

  • 市場定義和範圍
  • 市場區隔
  • 主要產品和服務概述
  • 全球心血管基因檢測市場：吸引力評分與分析
  • 成長潛力分析、競爭評估、策略適宜性評估、風險狀況評估

第3章 市場供應鏈分析

  • 供應鏈與生態系概述
  • 清單：主要原料、資源和供應商
  • 主要經銷商和通路合作夥伴名單
  • 主要最終用戶列表

第4章：全球市場趨勢與策略

  • 關鍵科技與未來趨勢
    • 生物技術、基因組學和精準醫療
    • 數位化、雲端運算、巨量資料、網路安全
    • 人工智慧（AI）和自主人工智慧
    • 工業4.0和智慧製造
    • 金融科技、區塊鏈、監管科技、數位金融
  • 主要趨勢
    • 擴大預測性遺傳風險評估的應用
    • 多基因檢測的擴展
    • 生物資訊學與人工智慧分析的融合正在不斷發展。
    • 拓展藥物基因體學檢測的應用範圍
    • 人們越來越關注個人化心血管護理

第5章 終端用戶產業市場分析

  • 醫院和診所
  • 診斷檢測實驗室
  • 研究機構
  • 遺傳諮詢中心
  • 製藥公司

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及 COVID-19 疫情對市場的影響。

第7章：全球策略分析架構、目前市場規模、市場對比及成長率分析

  • 全球心血管基因檢測市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 全球心血管基因檢測市場規模、對比及成長率分析
  • 全球心血管基因檢測市場表現：規模與成長，2020-2025年
  • 全球心血管基因檢測市場預測：規模與成長，2025-2030年，2035年預測

第8章：全球市場總規模（TAM）

第9章 市場細分

  • 按測試類型
  • 預測性測試、基因帶原檢測、產前和新生兒測試、診斷性測試、藥物基因測試和其他類型的測試。
  • 疾病特異性
  • 遺傳性心肌病、肥厚型心肌病（HCM）、擴大性心肌病（DCM）、心律不整、主動脈疾病及其他疾病
  • 透過技術
  • 細胞遺傳學檢測、生化檢測、分子檢測
  • 透過使用
  • 染色體分析、遺傳疾病診斷、心血管疾病診斷及其他應用。
  • 最終用戶
  • 醫院和診所、診斷檢測實驗室、研究機構、遺傳諮詢中心、製藥公司和直接消費者檢測。
  • 按類型細分：預測測試
  • 無症狀風險評估、遺傳性突變篩檢、多基因風險評估、晚發性疾病預測、易感基因檢測。
  • 按類型細分：基因帶原檢測
  • 常染色體隱性攜帶者篩檢、連鎖攜帶者篩檢、擴展攜帶者篩檢方案、單基因攜帶者篩檢、基於家族病史的基因帶原檢測
  • 按類型細分：產前和新生兒篩檢
  • 非侵入性產前基因檢測、侵入性產前診斷檢測、新生兒代謝篩檢、先天性心臟疾病基因篩檢、新生兒基因組檢測
  • 按類型細分：診斷測試
  • 單基因診斷檢測、多基因檢測、全EXOME顯子組診斷檢測、全基因組診斷檢測、突變確認檢測
  • 按類型細分：藥物基因體學組學檢測
  • 藥物反應基因檢測、藥物不良反應風險檢測、劑量最佳化基因檢測、抗凝血反應檢測、心血管藥物代謝檢測。
  • 按類型細分：其他測試類型
  • 級聯家族檢測、基於人群的基因篩檢、調查性基因檢測、確診和追蹤檢測、臨床試驗基因檢測

第10章 區域與國別分析

  • 全球心血管基因檢測市場：按地區分類，實際結果與預測，2020-2025年、2025-2030年預測、2035年預測
  • 全球心血管基因檢測市場：依國家分類，實際結果與預測，2020-2025年、2025-2030年預測、2035年預測

第11章 亞太市場

第12章：中國市場

第13章：印度市場

第14章：日本市場

第15章：澳洲市場

第16章：印尼市場

第17章：韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章 西歐市場

第21章英國市場

第22章：德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章：東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章：南美市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

  • 心血管基因檢測市場：競爭格局及市場佔有率（2024年）
  • 心血管基因檢測市場：公司估值矩陣
  • 心血管基因檢測市場：公司概況
    • Labcorp Holdings Inc.
    • Quest Diagnostics Inc.
    • ICON plc
    • Illumina Inc.
    • Apollo Hospitals

第37章 其他大型企業和創新企業

  • OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., Health in Code SL

第38章：全球市場競爭基準分析與儀錶板

第39章：預計進入市場的Start-Ups

第40章 重大併購

第41章 具有高市場潛力的國家、細分市場與策略

  • 2030年心血管基因檢測市場：提供新機會的國家
  • 2030年心血管基因檢測市場：新興細分市場機會
  • 2030年心血管基因檢測市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第42章附錄

簡介目錄
Product Code: HS5MCGTE01_G26Q1

Cardiovascular genetic testing involves examining an individual's DNA to detect inherited genetic variants that elevate the likelihood of developing diseases of the heart and blood vessels, supporting early identification, individualized treatment decisions, and focused preventive measures. It allows healthcare professionals to estimate disease risk, inform medication choices, evaluate hereditary predisposition, and facilitate proactive cardiovascular care through precision-based medical strategies.

The primary testing types of cardiovascular genetic testing include predictive testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, and other testing categories. Predictive testing consists of genetic assessments that evaluate an individual's likelihood of developing cardiovascular disorders prior to symptom onset. These tests are applied to diseases such as inherited cardiomyopathies, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmias, aortopathies, and other related conditions. The technologies involved include cytogenetic testing, biochemical testing, and molecular testing. The applications cover chromosome analysis, genetic disease identification, cardiovascular disease diagnosis, and other uses, while the end users include hospitals and clinics, diagnostic laboratories, research organizations, genetic counseling centers, pharmaceutical companies, and direct-to-consumer testing providers.

Tariffs are impacting the cardiovascular genetic testing market by increasing costs of imported sequencing instruments, reagents, bioinformatics hardware, and advanced laboratory equipment. Diagnostic laboratories and research institutions in North America and Europe are most affected due to reliance on imported genomic technologies, while Asia-Pacific faces higher costs for test kit manufacturing and distribution. These tariffs are increasing testing expenses and slowing laboratory expansion. However, they are also encouraging domestic reagent production, localized sequencing infrastructure, and regional bioinformatics platform development that strengthen long-term testing capacity.

The cardiovascular genetic testing market research report is one of a series of new reports from The Business Research Company that provides cardiovascular genetic testing market statistics, including cardiovascular genetic testing industry global market size, regional shares, competitors with a cardiovascular genetic testing market share, detailed cardiovascular genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular genetic testing industry. This cardiovascular genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiovascular genetic testing market size has grown rapidly in recent years. It will grow from $3.93 billion in 2025 to $4.35 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to increasing awareness of inherited cardiovascular disorders, expansion of molecular diagnostic capabilities, declining costs of genetic sequencing, growing use of genetic counseling services, increased research in cardiovascular genomics.

The cardiovascular genetic testing market size is expected to see rapid growth in the next few years. It will grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to increasing demand for precision medicine approaches, rising adoption of population-based genetic screening, expansion of AI-driven variant interpretation, growing integration of genomics in clinical decision making, increasing focus on preventive cardiovascular healthcare. Major trends in the forecast period include increasing adoption of predictive genetic risk assessment, rising use of multigene panel testing, growing integration of bioinformatics and AI analytics, expansion of pharmacogenomic testing applications, enhanced focus on personalized cardiovascular care.

The rising prevalence of cardiovascular diseases is projected to support the growth of the cardiovascular genetic testing market in the coming years. Cardiovascular diseases (CVDs) include a range of disorders affecting the heart and blood vessels, such as heart attacks, strokes, and hypertension. The prevalence of cardiovascular diseases is increasing largely due to sedentary lifestyles linked to urbanization, which contribute to obesity, high blood pressure, and metabolic conditions. The growing incidence of cardiovascular diseases increases demand for cardiovascular genetic testing, as early identification of genetic risks enables personalized prevention strategies and targeted treatments to reduce the risk of severe heart complications. For example, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, representing a 4.0% increase from 224.4 per 100,000 in 2023. Therefore, the rising prevalence of cardiovascular diseases is contributing to the growth of the cardiovascular genetic testing market.

Leading companies operating in the cardiovascular genetic testing market are concentrating on developing innovative solutions, such as clinician-ordered tests, to ensure medical necessity and customization based on patient-specific conditions, reducing unnecessary testing and associated costs. A clinician-ordered test is a diagnostic procedure requested by a healthcare professional to assess, monitor, or guide the management of a patient's health condition. For instance, in September 2025, Mass General Brigham, a US-based not-for-profit integrated academic healthcare system, in partnership with Broad Clinical Labs and the Mass General Brigham Laboratory for Molecular Medicine, launched a genetic test evaluating inherited risk for eight cardiovascular conditions. The clinician-ordered test is offered on a self-pay basis and assesses genetic predisposition to conditions such as atrial fibrillation, coronary artery disease, type 2 diabetes, elevated lipoprotein(a), hypercholesterolemia, hypertension, thoracic aortic aneurysm, and venous thromboembolism. Its development utilized genotype and clinical data from 236,393 participants in the NIH's All of Us Research Program. Publicly available polygenic risk scores were integrated using PRSmix, an elastic-net modeling approach combining multiple component scores into a single comprehensive risk score per disease. High-resolution genetic data is captured through a blended genome-exome assay at Broad Clinical Labs, while the CLIA-certified Mass General Brigham Laboratory for Molecular Medicine interprets results and generates patient-friendly reports.

In February 2025, Tempus AI Inc., a US-based precision medicine company, acquired Ambry Genetics for an undisclosed amount. This acquisition strengthens Tempus AI's strategy of combining diagnostics and data-driven insights to fuel innovation, enhancing its ability to deliver advanced solutions to healthcare providers, patients, and life sciences organizations. Ambry Genetics Corporation is a US-based company focused on cardiovascular genetic testing services.

Major companies operating in the cardiovascular genetic testing market are Labcorp Holdings Inc., Quest Diagnostics Inc., ICON plc, Illumina Inc., Apollo Hospitals, OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., and Health in Code SL.

North America was the largest region in the cardiovascular genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiovascular genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cardiovascular genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cardiovascular genetic testing market includes revenues earned by entities through genetic testing services, genetic screening services, molecular diagnostic services, genomic sequencing services, variant interpretation services, bioinformatics analysis services, genetic counseling services, and personalized risk assessment services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cardiovascular Genetic Testing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses cardiovascular genetic testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cardiovascular genetic testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cardiovascular genetic testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Testing Type: Predictive Testing; Carrier Testing; Prenatal And Newborn Testing; Diagnostic Testing; Pharmacogenomic Testing; Other Testing Types
  • 2) By Disease: Inherited Cardiomyopathies; Hypertrophic Cardiomyopathy (HCM); Dilated Cardiomyopathy (DCM); Arrhythmia; Aortopathies; Other Diseases
  • 3) By Technology: Cytogenetic Testing; Biochemical Testing; Molecular Testing
  • 4) By Application: Chromosome Analysis; Genetic Disease Diagnosis; Cardiovascular Disease Diagnosis; Other Applications
  • 5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutions; Genetic Counseling Centers; Pharmaceutical Companies; Direct-To-Consumer Testing
  • Subsegments:
  • 1) By Predictive Testing: Presymptomatic Risk Assessment; Familial Variant Screening; Polygenic Risk Evaluation; Late Onset Disease Prediction; Susceptibility Gene Testing
  • 2) By Carrier Testing: Autosomal Recessive Carrier Screening; Linked Carrier Screening; Expanded Carrier Screening Panels; Single Gene Carrier Screening; Family History Based Carrier Testing
  • 3) By Prenatal And Newborn Testing: Non Invasive Prenatal Genetic Testing; Invasive Prenatal Diagnostic Testing; Newborn Metabolic Screening; Congenital Heart Disease Genetic Screening; Neonatal Gene Panel Testing
  • 4) By Diagnostic Testing: Single Gene Diagnostic Testing; Multigene Panel Diagnostic Testing; Whole Exome Diagnostic Testing; Whole Genome Diagnostic Testing; Variant Confirmation Testing
  • 5) By Pharmacogenomic Testing: Drug Response Gene Testing; Adverse Drug Reaction Risk Testing; Dose Optimization Genetic Testing; Anticoagulant Response Testing; Cardiovascular Drug Metabolism Testing
  • 6) By Other Testing Types: Cascade Family Testing; Population Based Genetic Screening; Research Use Genetic Testing; Confirmatory Follow Up Testing; Clinical Trial Genetic Testing
  • Companies Mentioned: Labcorp Holdings Inc.; Quest Diagnostics Inc.; ICON plc; Illumina Inc.; Apollo Hospitals; OPKO Health Inc.; Revvity Inc.; ARUP Laboratories Inc.; Mayo Clinic Laboratories; Fulgent Genetics Inc.; MedGenome Inc.; Genome Medical; PreventionGenetics; Eurofins Genomics LLC; Blueprint Genetics Inc.; MapmyGenome; GENinCode; Allelica Srl; Rocket Pharma Inc.; and Health in Code SL.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Cardiovascular Genetic Testing Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Cardiovascular Genetic Testing Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Cardiovascular Genetic Testing Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Cardiovascular Genetic Testing Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.3 Artificial Intelligence & Autonomous Intelligence
    • 4.1.4 Industry 4.0 & Intelligent Manufacturing
    • 4.1.5 Fintech, Blockchain, Regtech & Digital Finance
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Predictive Genetic Risk Assessment
    • 4.2.2 Rising Use Of Multigene Panel Testing
    • 4.2.3 Growing Integration Of Bioinformatics And AI Analytics
    • 4.2.4 Expansion Of Pharmacogenomic Testing Applications
    • 4.2.5 Enhanced Focus On Personalized Cardiovascular Care

5. Cardiovascular Genetic Testing Market Analysis Of End Use Industries

  • 5.1 Hospitals And Clinics
  • 5.2 Diagnostic Laboratories
  • 5.3 Research Institutions
  • 5.4 Genetic Counseling Centers
  • 5.5 Pharmaceutical Companies

6. Cardiovascular Genetic Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Cardiovascular Genetic Testing Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Cardiovascular Genetic Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Cardiovascular Genetic Testing Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Cardiovascular Genetic Testing Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Cardiovascular Genetic Testing Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Cardiovascular Genetic Testing Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Cardiovascular Genetic Testing Market Segmentation

  • 9.1. Global Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Predictive Testing, Carrier Testing, Prenatal And Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Other Testing Types
  • 9.2. Global Cardiovascular Genetic Testing Market, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Inherited Cardiomyopathies, Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Arrhythmia, Aortopathies, Other Diseases
  • 9.3. Global Cardiovascular Genetic Testing Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cytogenetic Testing, Biochemical Testing, Molecular Testing
  • 9.4. Global Cardiovascular Genetic Testing Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Chromosome Analysis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, Other Applications
  • 9.5. Global Cardiovascular Genetic Testing Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals And Clinics, Diagnostic Laboratories, Research Institutions, Genetic Counseling Centers, Pharmaceutical Companies, Direct-To-Consumer Testing
  • 9.6. Global Cardiovascular Genetic Testing Market, Sub-Segmentation Of Predictive Testing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Presymptomatic Risk Assessment, Familial Variant Screening, Polygenic Risk Evaluation, Late Onset Disease Prediction, Susceptibility Gene Testing
  • 9.7. Global Cardiovascular Genetic Testing Market, Sub-Segmentation Of Carrier Testing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Autosomal Recessive Carrier Screening, Linked Carrier Screening, Expanded Carrier Screening Panels, Single Gene Carrier Screening, Family History Based Carrier Testing
  • 9.8. Global Cardiovascular Genetic Testing Market, Sub-Segmentation Of Prenatal And Newborn Testing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Non Invasive Prenatal Genetic Testing, Invasive Prenatal Diagnostic Testing, Newborn Metabolic Screening, Congenital Heart Disease Genetic Screening, Neonatal Gene Panel Testing
  • 9.9. Global Cardiovascular Genetic Testing Market, Sub-Segmentation Of Diagnostic Testing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Single Gene Diagnostic Testing, Multigene Panel Diagnostic Testing, Whole Exome Diagnostic Testing, Whole Genome Diagnostic Testing, Variant Confirmation Testing
  • 9.10. Global Cardiovascular Genetic Testing Market, Sub-Segmentation Of Pharmacogenomic Testing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Drug Response Gene Testing, Adverse Drug Reaction Risk Testing, Dose Optimization Genetic Testing, Anticoagulant Response Testing, Cardiovascular Drug Metabolism Testing
  • 9.11. Global Cardiovascular Genetic Testing Market, Sub-Segmentation Of Other Testing Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cascade Family Testing, Population Based Genetic Screening, Research Use Genetic Testing, Confirmatory Follow Up Testing, Clinical Trial Genetic Testing

10. Cardiovascular Genetic Testing Market Regional And Country Analysis

  • 10.1. Global Cardiovascular Genetic Testing Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Cardiovascular Genetic Testing Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Cardiovascular Genetic Testing Market

  • 11.1. Asia-Pacific Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Cardiovascular Genetic Testing Market

  • 12.1. China Cardiovascular Genetic Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Cardiovascular Genetic Testing Market

  • 13.1. India Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Cardiovascular Genetic Testing Market

  • 14.1. Japan Cardiovascular Genetic Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Cardiovascular Genetic Testing Market

  • 15.1. Australia Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Cardiovascular Genetic Testing Market

  • 16.1. Indonesia Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Cardiovascular Genetic Testing Market

  • 17.1. South Korea Cardiovascular Genetic Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Cardiovascular Genetic Testing Market

  • 18.1. Taiwan Cardiovascular Genetic Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Cardiovascular Genetic Testing Market

  • 19.1. South East Asia Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Cardiovascular Genetic Testing Market

  • 20.1. Western Europe Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Cardiovascular Genetic Testing Market

  • 21.1. UK Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Cardiovascular Genetic Testing Market

  • 22.1. Germany Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Cardiovascular Genetic Testing Market

  • 23.1. France Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Cardiovascular Genetic Testing Market

  • 24.1. Italy Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Cardiovascular Genetic Testing Market

  • 25.1. Spain Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Cardiovascular Genetic Testing Market

  • 26.1. Eastern Europe Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Cardiovascular Genetic Testing Market

  • 27.1. Russia Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Cardiovascular Genetic Testing Market

  • 28.1. North America Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Cardiovascular Genetic Testing Market

  • 29.1. USA Cardiovascular Genetic Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Cardiovascular Genetic Testing Market

  • 30.1. Canada Cardiovascular Genetic Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Cardiovascular Genetic Testing Market

  • 31.1. South America Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Cardiovascular Genetic Testing Market

  • 32.1. Brazil Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Cardiovascular Genetic Testing Market

  • 33.1. Middle East Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Cardiovascular Genetic Testing Market

  • 34.1. Africa Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Cardiovascular Genetic Testing Market Regulatory and Investment Landscape

36. Cardiovascular Genetic Testing Market Competitive Landscape And Company Profiles

  • 36.1. Cardiovascular Genetic Testing Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Cardiovascular Genetic Testing Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Cardiovascular Genetic Testing Market Company Profiles
    • 36.3.1. Labcorp Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Quest Diagnostics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. ICON plc Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Apollo Hospitals Overview, Products and Services, Strategy and Financial Analysis

37. Cardiovascular Genetic Testing Market Other Major And Innovative Companies

  • OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., Health in Code SL

38. Global Cardiovascular Genetic Testing Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Cardiovascular Genetic Testing Market

41. Cardiovascular Genetic Testing Market High Potential Countries, Segments and Strategies

  • 41.1 Cardiovascular Genetic Testing Market In 2030 - Countries Offering Most New Opportunities
  • 41.2 Cardiovascular Genetic Testing Market In 2030 - Segments Offering Most New Opportunities
  • 41.3 Cardiovascular Genetic Testing Market In 2030 - Growth Strategies
    • 41.3.1 Market Trend Based Strategies
    • 41.3.2 Competitor Strategies

42. Appendix

  • 42.1. Abbreviations
  • 42.2. Currencies
  • 42.3. Historic And Forecast Inflation Rates
  • 42.4. Research Inquiries
  • 42.5. The Business Research Company
  • 42.6. Copyright And Disclaimer